Furthermore, Kaplan–Meier analysis indicated that high MAOA expression was correlated with poor PFS in 58 high risk PC patients developing into CRPC and receiving abiraterone therapy, the low-MAOA-expression group had a 1-year PFS rate of 60% versus a 1-year PFS rate of 26.7% in the high-MAOA-expression group (log-rank: P = 0.01) (Fig. 4). Here, MAOA is linked to pachyonychia congenita.